<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2444-054X</journal-id>
<journal-title><![CDATA[Cirugía y cirujanos]]></journal-title>
<abbrev-journal-title><![CDATA[Cir. cir.]]></abbrev-journal-title>
<issn>2444-054X</issn>
<publisher>
<publisher-name><![CDATA[Academia Mexicana de Cirugía A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2444-054X2025000100009</article-id>
<article-id pub-id-type="doi">10.24875/ciru.23000122</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Decreased plasma visfatin concentrations in pediatric aneurysmal bone cyst: a pilot study]]></article-title>
<article-title xml:lang="es"><![CDATA[Disminución de las concentraciones plasmáticas de visfatina en el quiste óseo aneurismático pediátrico: un estudio piloto]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ulus]]></surname>
<given-names><![CDATA[Sait A.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Özkul]]></surname>
<given-names><![CDATA[Emin]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Dicle University Medical School Department of Orthopedics and Traumatology ]]></institution>
<addr-line><![CDATA[Diyarbak&#305;r ]]></addr-line>
<country>Turkey</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>02</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>02</month>
<year>2025</year>
</pub-date>
<volume>93</volume>
<numero>1</numero>
<fpage>54</fpage>
<lpage>58</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2444-054X2025000100009&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2444-054X2025000100009&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2444-054X2025000100009&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Objective: This is a prospective study and visfatin values of patients with aneurysmal bone cysts (ABC) were compared with those of healthy individuals.  Method: This study consists of 20 patients diagnosed with ABC (Group 1) and 30 healthy patients (Group 2). Age, gender, cyst sizes, and visfatin values of all patients were recorded and evaluated.  Results: A total of 50 patients, 20 from Group 1 and 30 from Group 2, were included in our study. The mean age was 13.80 ± 3.98 years in Group 1 and 14.67 ± 4.24 years in Group 2, and no statistically significant difference was found between the groups (p &gt; 0.05). While 60% of the patients in Group 1 were male, in Group 2, 53% of the patients were male. Cyst area was recorded as 1171 (512-2310) mm2. The visfatin value was 10.70 ± 5.91 ng/mL in Group 1 and 15.23 ± 5.86 ng/mL in Group 2. The visfatin value in the ABC group was found to be statistically significantly lower than the control group (p &lt; 0.05). No correlation was found between cyst area and visfatin (p &gt; 0.05).  Conclusion: Our study found that visfatin levels are significantly lower in patients with ABC s compared to healthy controls, suggesting its potential as a diagnostic biomarker. The ROC analysis showed a good diagnostic ability.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Objetivo: Este es un estudio prospectivo en el cual se compararon los valores de visfatina de pacientes con quistes óseos aneurismáticos con los de individuos sanos.  Método: En el estudio participaron 20 pacientes diagnosticados de quiste óseo aneurismático (grupo 1) y 30 pacientes sanos (grupo 2).  Resultados: Se incluyeron en nuestro estudio un total de 50 pacientes, 20 del grupo 1 y 30 del grupo 2. La edad media fue de 13.80 ± 3,98 años en el grupo 1 y de 14.67 ± 4.24 años en el grupo 2, y no se encontró diferencia estadísticamente significativa entre ambos grupos (p &gt; 0.05). El área del quiste se registró como 1,171 mm2 (512-2,310 mm2). El valor de visfatina fue de 10.70 ± 5.91 ng/mL en el grupo 1 y de 15.23 ± 5.86 ng/mL en el grupo 2. Se encontró que el valor de visfatina en el grupo de quistes óseos aneurismáticos era significativamente menor desde el punto de vista estadístico que en el grupo de control (p &lt; 0.05). No se encontró correlación entre el área del quiste y la visfatina (p &gt; 0.05).  Conclusión: Nuestro estudio encontró que los niveles de visfatina son significativamente más bajos en pacientes con quistes óseos aneurismáticos en comparación con los controles sanos, lo que sugiere su potencial como biomarcador diagnóstico. El análisis ROC mostró una buena capacidad diagnóstica.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Visfatin]]></kwd>
<kwd lng="en"><![CDATA[Aneurysmal bone cyst]]></kwd>
<kwd lng="en"><![CDATA[Pediatric]]></kwd>
<kwd lng="es"><![CDATA[Visfatina]]></kwd>
<kwd lng="es"><![CDATA[Quiste óseo aneurismático]]></kwd>
<kwd lng="es"><![CDATA[Pediátrico]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rosenblatt]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Koder]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Understanding unicameral and aneurysmal bone cysts]]></article-title>
<source><![CDATA[Pediatr Rev]]></source>
<year>2019</year>
<volume>40</volume>
<page-range>51-9</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hu]]></surname>
<given-names><![CDATA[PF]]></given-names>
</name>
<name>
<surname><![CDATA[Bao]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[LD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The emerging role of adipokines in osteoarthritis:a narrative review]]></article-title>
<source><![CDATA[Mol Biol Rep]]></source>
<year>2011</year>
<volume>38</volume>
<page-range>873-8</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Junker]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Frommer]]></surname>
<given-names><![CDATA[KW]]></given-names>
</name>
<name>
<surname><![CDATA[Krumbholz]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Tsiklauri]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Gerstberger]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Rehart]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Expression of adipokines in osteoarthritis osteophytes and their effect on osteoblasts]]></article-title>
<source><![CDATA[Matrix Biol]]></source>
<year>2017</year>
<volume>62</volume>
<page-range>75-91</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Liao]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The current progress in understanding the molecular functions and mechanisms of visfatin in osteoarthritis]]></article-title>
<source><![CDATA[J Bone Miner Metab]]></source>
<year>2016</year>
<volume>34</volume>
<page-range>485-90</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Laiguillon]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Houard]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Bougault]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Gosset]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Nourissat]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Sautet]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Expression and function of visfatin (Nampt), an adipokine-enzyme involved in inflammatory pathways of osteoarthritis]]></article-title>
<source><![CDATA[Arthritis Res Ther]]></source>
<year>2014</year>
<volume>16</volume>
<page-range>R38</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chan]]></surname>
<given-names><![CDATA[TF]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[YL]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
<name>
<surname><![CDATA[Chou]]></surname>
<given-names><![CDATA[FH]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[LC]]></given-names>
</name>
<name>
<surname><![CDATA[Jong]]></surname>
<given-names><![CDATA[SB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Decreased plasma visfatin concentrations in women with gestational diabetes mellitus]]></article-title>
<source><![CDATA[J Soc Gynecol Investig]]></source>
<year>2006</year>
<volume>13</volume>
<page-range>364-7</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Duan]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Hao]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Increased synovial fluid visfatin is positively linked to cartilage degradation biomarkers in osteoarthritis]]></article-title>
<source><![CDATA[Rheumatol Int]]></source>
<year>2012</year>
<volume>32</volume>
<page-range>985-90</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gonzalez-Gay]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Vazquez-Rodriguez]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Garcia-Unzueta]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Berja]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[MirandaFilloy]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[De Matias]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Visfatin is not associated with inflammation or metabolic syndrome in patients with severe rheumatoid arthritis undergoing anti-TNF-&#945; therapy]]></article-title>
<source><![CDATA[Clin Exp Rheumatol]]></source>
<year>2010</year>
<volume>28</volume>
<page-range>56-63</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sezen]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Okumus]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Pehlivan]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Dilli]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Tarakcio&#287;lu]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Onat]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Visfatin levels in Behcet's disease]]></article-title>
<source><![CDATA[Inflammation]]></source>
<year>2012</year>
<volume>35</volume>
<page-range>405-8</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
